Indivior PLC stock (US45580R1068): Opioid-treatment specialist in focus after Q1 update and ongoing US listing plans

Indivior PLC remains in the spotlight after reporting its first-quarter 2026 results and progressing its US primary listing strategy. The maker of opioid-use-disorder treatments continues to reshape its portfolio and capital structure, a development closely watched by US healthcare investors.

Indivior PLC stock has drawn renewed attention from healthcare-focused investors after the specialty pharmaceuticals group reported its first-quarter 2026 results and updated markets on its strategy to prioritize a US primary listing, reflecting the company’s revenue exposure and investor base in North America, according to Indivior press materials as of 05/2026.

In its recent quarterly communication, the company behind opioid-use-disorder treatments such as Suboxone and Sublocade highlighted ongoing growth in its long-acting injectable portfolio, alongside continued legal and settlement-related outflows that still shape investor perception of the stock, as summarized by Reuters as of 05/2026.

As of: 08.06.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Indivior PLC
• Sector/industry: Specialty pharmaceuticals / addiction treatment
• Headquarters/country: United Kingdom
• Core markets: United States, with additional international exposure
• Key revenue drivers: Opioid-use-disorder therapies, especially long-acting injectables
• Home exchange/listing venue: London Stock Exchange (INDV), secondary US listing via ADR
• Trading currency: Primarily GBP in London; ADR quoted in USD

Indivior PLC: core business model

Indivior PLC is a specialty pharmaceutical company focused on the treatment of substance-use disorders, with a particular emphasis on opioid-use disorder therapies that target a significant medical and public-health challenge in the United States, according to Indivior company information as of 2025.

The company’s business model centers on developing, manufacturing and commercializing medications that combine pharmacological efficacy with formulations designed to reduce misuse and improve patient adherence, which is especially relevant in the context of long-term addiction management, as discussed in Indivior therapy overviews as of 2025.

Historically, Indivior derived a substantial portion of its revenue from Suboxone, a buprenorphine-based product for opioid-use disorder that faced generic competition in the United States in recent years, prompting the company to accelerate a strategic shift toward newer formulations and products, according to Reuters as of 04/2019.

In response to this patent-expiry and competition pressure, Indivior has concentrated its R&D and commercial resources on long-acting injectable therapies such as Sublocade, which target patients requiring sustained, once-monthly dosing to stabilize treatment outcomes and reduce the risk of relapse, as indicated by Indivior product information as of 2025.

The company’s commercial model is heavily weighted toward the United States market, where reimbursement structures, prescribing patterns and the scale of the opioid epidemic create a significant addressable market, which in turn supports Indivior’s strategic decision to pursue a primary listing in the US, according to Indivior press release as of 07/2023.

Beyond addiction medicine, Indivior maintains a pipeline of research programs aimed at expanding its presence into adjacent behavioral health indications, though these earlier-stage assets contribute less to near-term revenue visibility than the company’s established opioid-use-disorder portfolio, based on disclosures in Indivior investor presentations as of 2025.

This focused portfolio strategy differentiates Indivior from diversified large-cap pharmaceutical companies, positioning it as a more concentrated play on the dynamics of the US addiction-treatment market, which can amplify both upside potential and risk depending on regulatory and reimbursement developments, as highlighted by Financial Times coverage as of 2024.

Main revenue and product drivers for Indivior PLC

The key revenue driver for Indivior is Sublocade, its once-monthly injectable buprenorphine product for opioid-use disorder that has experienced robust adoption in the US as clinicians and payers increasingly recognize the benefits of long-acting formulations in treatment adherence, according to Indivior FY 2024 results as of 02/2025.

In the company’s full-year 2024 report, management noted that Sublocade net revenue grew strongly year-on-year, contributing an increasing share of the group’s total net revenue and partially offsetting erosion in legacy Suboxone sales, as stated in Indivior FY 2024 earnings release as of 02/2025.

Suboxone, while still meaningful in some markets, has been under sustained competitive pressure from generic alternatives in the United States, leading to a progressive decline in its revenue contribution and reinforcing the strategic imperative for Indivior to pivot its product mix toward newer, differentiated offerings, according to Reuters as of 07/2019.

Other products in Indivior’s portfolio include treatments for alcohol-use disorder and related conditions, though these currently contribute a smaller share of net revenue compared with the opioid-use-disorder franchise, based on information from Indivior therapy overviews as of 2025.

Looking at the first quarter of 2026, Indivior reported continued growth in Sublocade prescriptions and revenue, underpinned by expanding access in US public and commercial payer channels, according to management commentary summarized in Indivior Q1 2026 trading update as of 05/2026.

The company’s margin profile reflects the capital and R&D intensity of specialty pharmaceuticals as well as ongoing legal and settlement payments related to historic marketing practices, which have periodically weighed on reported net income despite growing topline contributions from Sublocade, as noted in Reuters as of 06/2023.

Management has emphasized disciplined cost control and targeted investment in commercialization activities to support the scaling of Sublocade, alongside efforts to optimize the group’s capital structure through share buyback authorizations and debt management, as referenced in Indivior share repurchase announcement as of 09/2024.

For investors, a central question is the pace at which Sublocade can capture further share in the US opioid-use-disorder market relative to competing products and generics, given the company’s guidance that long-acting injectables represent a key pillar of its medium-term growth strategy, according to Indivior capital markets event materials as of 11/2024.

Conclusion

Indivior PLC remains a focused player in the addiction-treatment segment, with Sublocade driving a growing share of revenue and underpinning its strategic tilt toward a US-centered investor base. At the same time, legacy legal issues, competitive pressure on older products and the execution of a planned US primary listing create moving parts that investors weigh carefully. For US market participants, the stock offers targeted exposure to the dynamics of the opioid-use-disorder treatment market, with both regulatory developments and commercial momentum likely to play an important role in future valuation.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.